MedTrace Logo

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

NCT04971200 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-12

No results posted yet for this study

Summary

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

Conditions

  • Skin and Connective Tissue Diseases
  • Skin Diseases
  • Pigmentation Disorder
  • Hypopigmentation
  • Biologic
  • Vitiligo

Interventions

DRUG

Tildrakizumab

2 100mg subcutaneous injections Q4W

Sponsors & Collaborators

  • Premier Specialists, Australia

    lead OTHER

Principal Investigators

  • Dedee Murrell, MD · University of New South Wales

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2024-11-10
Completion
2024-11-10

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04971200 on ClinicalTrials.gov